Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes mortality due to rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes acute hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Chronic hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes chronic hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes mortality due to rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes acute hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Chronic hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes chronic hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether total shunt changes all‐cause mortality compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether total shunt changes rebleeding compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean number of wet nights a week · children with nocturnal enuresis
1 finding from 1 review
Proportion of children achieving 14 consecutive dry nights by the end of treatment · children with nocturnal enuresis
Alarm showed no clear difference in proportion of children achieving 14 consecutive dry nights by the… compared with other behavioural interventions (low certainty).
1 finding from 1 review
Proportion of children dry at · children with nocturnal enuresis
Alarm showed no clear difference in proportion of children dry at compared with other behavioural interventions (low certainty).
1 finding from 1 review
Proportion of children with adverse events · children with nocturnal enuresis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (low certainty).
1 finding from 1 review
Intervention not reported
Mitoxantrone (Direct evidence; 1 RCT; 51 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower mitoxantrone (Direct evidence; 1 RCT; 51 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Natalizumab (Direct evidence; 1 RCT; 942 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention leads to lower natalizumab (Direct evidence; 1 RCT; 942 participants) (high certainty).
1 finding from 1 review
Intervention not reported
Teriflunomide (Direct evidence; 1 RCT; 1169 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower teriflunomide (Direct evidence; 1 RCT; 1169 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Placebo · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention leads to lower alemtuzumab No direct evidence (high certainty).
1 finding from 1 review
RR 0.57 [0.47, 0.68]
Studies not reported
High